| scholarly article | Q13442814 |
| P356 | DOI | 10.18632/ONCOTARGET.21371 |
| P8608 | Fatcat ID | release_b3sx7yn5tncppopigw4cie3mpi |
| P932 | PMC publication ID | 5722549 |
| P698 | PubMed publication ID | 29228597 |
| P50 | author | So Yeon Park | Q40419435 |
| P2093 | author name string | Young A Kim | |
| Hyun Jeong Kim | |||
| Ki-Tae Hwang | |||
| Mee Soo Chang | |||
| Yul Ri Chung | |||
| P2860 | cites work | Breast cancer intra-tumor heterogeneity | Q27000086 |
| FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer | Q27851554 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| Tumour evolution inferred by single-cell sequencing | Q28646966 | ||
| Measurement of Diversity | Q29303177 | ||
| The landscape of somatic copy-number alteration across human cancers | Q29547648 | ||
| Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma | Q29615604 | ||
| Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype | Q33604942 | ||
| Genomic instability in breast cancer: pathogenesis and clinical implications | Q33998514 | ||
| PIK3CA mutations in in situ and invasive breast carcinomas | Q34001222 | ||
| Genetic clonal diversity predicts progression to esophageal adenocarcinoma | Q34505745 | ||
| Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Q35130819 | ||
| A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables | Q35640223 | ||
| FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis | Q35794378 | ||
| Subclonal diversification of primary breast cancer revealed by multiregion sequencing | Q35847434 | ||
| The 8q24 gene desert: an oasis of non-coding transcriptional activity. | Q35919877 | ||
| In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer | Q36109108 | ||
| C-myc amplification in breast cancer: a meta-analysis of its occurrence and prognostic relevance | Q36621638 | ||
| Intratumoral Heterogeneity of the Epigenome. | Q36854908 | ||
| FGFR1 is amplified during the progression of in situ to invasive breast carcinoma | Q36924421 | ||
| Breast tumor heterogeneity: cancer stem cells or clonal evolution? | Q36929348 | ||
| Pan-cancer analysis of intratumor heterogeneity as a prognostic determinant of survival | Q36962873 | ||
| Chromosomal instability and copy number alterations in Barrett's esophagus and esophageal adenocarcinoma | Q37198249 | ||
| Co-evolution of tumor cells and their microenvironment | Q37340741 | ||
| Detection of gene copy number alterations in DCIS and invasive breast cancer by QM-FISH. | Q37448213 | ||
| Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity | Q37592617 | ||
| Genetic and phenotypic diversity in breast tumor metastases | Q37659374 | ||
| Cellular heterogeneity and molecular evolution in cancer | Q38054794 | ||
| Intratumor Heterogeneity in Breast Cancer | Q38778540 | ||
| Tumor heterogeneity and the biology of cancer invasion and metastasis | Q39759977 | ||
| Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab | Q41344399 | ||
| c-MYC-induced genomic instability. | Q42127661 | ||
| Integrated profiling of basal and luminal breast cancers. | Q42522755 | ||
| Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution | Q42524058 | ||
| Intratumoral heterogeneity of HER2 gene amplification in breast cancer: its clinicopathological significance | Q44838384 | ||
| The mathematical theory of communication. 1963. | Q48828107 | ||
| Evaluating tumor heterogeneity in immunohistochemistry-stained breast cancer tissue. | Q51556494 | ||
| Intratumor heterogeneity: seeing the wood for the trees. | Q53097757 | ||
| Intratumoral heterogeneity of microRNA expression in breast cancer. | Q53101232 | ||
| HER2 heterogeneity affects trastuzumab responses and survival in patients with HER2-positive metastatic breast cancer. | Q53251318 | ||
| Genetic heterogeneity in HER2 testing in breast cancer: panel summary and guidelines | Q83722585 | ||
| Genetic heterogeneity and cancer drug resistance | Q83791245 | ||
| P433 | issue | 57 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | diversity index | Q1230601 |
| P304 | page(s) | 97114-97126 | |
| P577 | publication date | 2017-09-28 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | Diversity index as a novel prognostic factor in breast cancer | |
| P478 | volume | 8 |
Search more.